澳洋健康(002172) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥581,691,001.68, representing a 6.95% increase compared to ¥543,869,982.70 in the same period last year[4]. - Net profit attributable to shareholders decreased by 15.39% to ¥30,739,368.29 from ¥36,326,684.73 year-on-year[4]. - The net profit after deducting non-recurring gains and losses increased by 138.50% to ¥27,855,342.48 from ¥11,677,474.17 in the previous year[4]. - Basic and diluted earnings per share both decreased by 20.00% to ¥0.04 from ¥0.05 in the same period last year[4]. - The weighted average return on equity dropped to 28.14%, down 30.05% from 58.19% in the previous year[4]. - The company's net loss for Q1 2024 was CNY 4,465,533.43, compared to a loss of CNY 4,972,320.57 in Q1 2023, indicating a slight improvement in financial performance[16]. - The total profit for the current period is ¥38,810,915.19, down from ¥41,199,376.44, reflecting a decline of 5.8%[18]. - Operating income for the current period is ¥35,955,833.29, compared to ¥41,107,031.09 in the previous period, indicating a decrease of 12.5%[18]. Cash Flow and Liquidity - Cash flow from operating activities showed a significant decline, with a net outflow of ¥212,015,808.16, a 74.82% increase in outflow compared to ¥121,279,156.93 last year[4]. - Cash and cash equivalents decreased to CNY 552,186,435.39 from CNY 707,373,097.67, a decline of 21.9%[14]. - Cash and cash equivalents at the end of the period increased to ¥418,744,268.63 from ¥198,650,121.57, marking a significant improvement[22]. - The total cash outflow from operating activities was ¥889,310,880.92, compared to ¥801,393,234.80 in the previous period, an increase of 10.9%[21]. - The company reported cash inflows from financing activities of ¥671,846,211.49, up from ¥551,934,820.35 in the previous period, an increase of 21.7%[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,200,581,232.92, a decrease of 1.82% from ¥2,241,371,837.83 at the end of the previous year[4]. - Total liabilities decreased to CNY 2,091,894,042.87 from CNY 2,166,565,617.51, a decline of 3.4%[15]. - Total non-current liabilities increased by 40.82% compared to the beginning of the period, primarily due to an increase in financing lease payments at the end of the period[11]. - Total equity increased by 45.29% compared to the beginning of the period, mainly due to an increase in profits for the period[11]. Shareholder Information - Shareholders' equity attributable to the parent company increased by 32.74% to ¥124,616,584.33 from ¥93,877,216.04 at the end of the previous year[4]. - The number of ordinary shareholders at the end of the reporting period was 59,900, with the largest shareholder holding 30.74% of the shares[12]. - The company's equity attributable to shareholders increased to CNY 124,616,584.33 from CNY 93,877,216.04, a growth of 32.8%[16]. Accounting and Policy Changes - The company implemented changes in accounting policies as per the "Interpretation No. 16 of the Accounting Standards for Enterprises," affecting the recognition of deferred tax assets and liabilities[5]. - The company plans to implement new accounting standards starting January 1, 2024, which may affect financial reporting[23]. - The company has not undergone an audit for the first quarter report[24]. Other Financial Metrics - Cash and cash equivalents increased by 141.45% compared to the same period last year, mainly due to an increase in borrowed funds received[11]. - Financial expenses decreased by 185.77% compared to the same period last year, mainly due to increased interest income from matured time deposits used for guarantees[11]. - Investment income decreased by 101.50% compared to the same period last year, primarily due to gains from the disposal of subsidiaries in the previous period[11]. - The company reported a significant increase in inventory, which rose to CNY 186,121,061.94 from CNY 183,417,853.92, reflecting a 1.5% increase[14]. - Accounts receivable financing increased by 164.90% compared to the beginning of the period, mainly due to an increase in the amount of notes receivable used for endorsement and discounting[11]. - Goodwill increased by 173.96% compared to the beginning of the period, primarily due to goodwill generated from the merger with Aoyang Daling under non-common control[11]. - Contract liabilities increased by 123.98% compared to the beginning of the period, mainly due to an increase in pre-received medical service-related payments at the end of the period[11]. - Accounts receivable increased to CNY 357,015,522.36, up 22.6% from CNY 291,267,583.43 at the beginning of the period[14].